Related Experiment Video

Updated: Feb 12, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.0K

Olaparib for the treatment of breast cancer

Gaia Griguolo1,2, Maria Vittoria Dieci1,2, Valentina Guarneri1,2

  • 1a Department of Surgery, Oncology and Gastroenterology , University of Padova , Padova , Italy.

Expert Review of Anticancer Therapy
|March 28, 2018
PubMed
Abstract

Insights

Olaparib, a PARP inhibitor, significantly improves progression-free survival for patients with BRCA-mutated HER2-negative metastatic breast cancer. This targeted therapy shows particular efficacy in triple-negative breast cancer, offering a manageable safety profile.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • BRCA1 and BRCA2 gene mutations are implicated in 2-3% of all breast cancers and over 10% of triple-negative breast cancers.
  • Metastatic breast cancer with BRCA mutations presents a significant clinical challenge.
  • PARP inhibitors represent a targeted therapeutic approach for DNA repair-deficient cancers.

Purpose of the Study:

  • To review preclinical and clinical data on olaparib for breast cancer treatment.
  • To evaluate the efficacy and safety of olaparib in BRCA-mutated HER2-negative metastatic breast cancer.
  • To discuss the role of olaparib in the context of triple-negative breast cancer.

Main Methods:

  • Review of published preclinical studies and clinical trial data for olaparib.
  • Analysis of olaparib's chemistry, mechanism of action, pharmacokinetics, and pharmacodynamics.
  • Evaluation of antitumor efficacy and safety data from Phase III trials.

Main Results:

  • Olaparib demonstrated clinical benefit in a Phase III trial for BRCA-mutated HER2-negative metastatic breast cancer.
  • Improved progression-free survival compared to standard chemotherapy was observed.
  • A manageable toxicity profile was reported, with particular relevance in triple-negative breast cancer.

Conclusions:

  • Olaparib is an effective treatment option for patients with germline BRCA-mutated HER2-negative metastatic breast cancer.
  • Its efficacy is especially notable in triple-negative breast cancer subtypes.
  • Further research is needed on optimal sequencing, combination therapies, and biomarker identification.
Keywords:
BRCAOlaparibOlympiAD trialPARP inhibitorsbreast cancersynthetic lethality

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.1K
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
976
What is Cancer?02:12

What is Cancer?

Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
14.5K